Clinical Trial

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

Study acronym: TeLuRide-008
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.
Protocol Amendment History 4 changes
notable Trial sites expanded: 10 -> 14 locations 2026-08-07
notable Trial sites expanded: 3 -> 10 locations 2026-07-16
critical Recruitment opened 2026-05-21
notable Trial sites expanded: 0 -> 3 locations 2026-05-21
Trial Details
NCT Number NCT07365319
Lead Sponsor Eikon Therapeutics
Collaborators: Merck Sharp & Dohme LLC
Conditions Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC
Enrollment 750 participants
Start Date 2026-06-15
Primary Completion 2035-12-31 (estimated)
Study Completion 2040-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-06